According to the recent guideline from the American Society of Clinical Oncology (ASCO) (162), all women with ovarian cancers irrespective of histological subtypes should have germline genetic tests of ovarian cancer susceptibility genes as a multigene panel that should at least include BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, MLH1, MSH2, MSH6, PMS2, and PALB2. Somatic genetic testing on tumor tissue should be performed if germline pathogenic or likely pathogenic variants cannot be found. This evidence concerns the gene BRCA1 and ovarian cancer.